CompletedPhase 2NCT02589236
Study of Cavosonstat (N91115) in Patients With CF Homozygous for the F508del-CFTR Mutation
Studying Cystic fibrosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Nivalis Therapeutics, Inc.
- Principal Investigator
- Scott Donaldson, MDUniversity of North Carolina, Chapel Hill
- Intervention
- Cavosonstat(drug)
- Enrollment
- 138 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2015 – 2016
Study locations (30)
- University of Alabama, Birmingham, Alabama, United States
- Banner University of Arizona Medical Center, Tucson, Arizona, United States
- Children's Hospital Los Angeles, Los Angeles, California, United States
- Stanford University, Palo Alto, California, United States
- UC Davis Medical Center, Sacramento, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- National Jewish Health, Denver, Colorado, United States
- Yale University, New Haven, Connecticut, United States
- Tampa General Hospital, Tampa, Florida, United States
- St. Luke's CF Center of Idaho, Boise, Idaho, United States
- Northwestern University, Chicago, Illinois, United States
- Saint Francis Medical Center, Peoria, Illinois, United States
- Indiana University, Indianapolis, Indiana, United States
- University of Iowa Children's Hospital, Iowa City, Iowa, United States
- Via Christi Research, Wichita, Kansas, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Medidata Solutions
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02589236 on ClinicalTrials.govOther trials for Cystic fibrosis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT04530383Metformin for People With CFRD on CFTR Modulator Therapy to Improve Ion Channel FunctionUniversity of Kansas Medical Center
- RECRUITINGPHASE2NCT07450547Phase 2 Study to Assess the Safety and Efficacy of ANG003Anagram Therapeutics, Inc.
- RECRUITINGPHASE1NCT07437105Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy ParticipantsVertex Pharmaceuticals Incorporated
- RECRUITINGNANCT07436351ACT With CF Self-Help ToolkitThomas Jefferson University
- RECRUITINGNANCT07314229Prevalence of Exercise-induced Ventilatory Limitation and Associated Factors in Patients With Cystic Fibrosis Receiving Elexacaftor-Tezacaftor-IvacaftorUniversity Hospital, Lille
- RECRUITINGNCT07083557Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)Bettina Mittendorfer
- RECRUITINGNCT07369414Environmental Reservoirs of Non-tuberculous Mycobacteria in Cystic Fibrosis Households: A Case-control Study of Exposure Risk at HomeResearch Center Borstel
- RECRUITINGNCT07505797ATUSA Ultrasound Diagnostic Imaging for Breast Lesions Evaluation (AUDIBLE)iSono Health, Inc.